ANN ARBOR, MI--(MARKET WIRE)--Sep 21, 2007 -- Pipex Pharmaceuticals, Inc. (AMEX:PP - News), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that it completed a series of pre-NDA meetings with the FDA yesterday regarding its lead drug candidate, COPREXA (oral tetrathiomolybdate), and that in November Pipex plans to submit its New Drug Application (NDA) for COPREXA for the treatment of initially-presenting neurologic Wilson's disease.
